Degussa Aktiengesellschaft

Other

Forschungszentrum J&#xdc;lich Gmbh

Carsten Bolm

Karlheinz Drauz

Andreas Bommarius

Arne Gerlach

Christian Wandrey

Udo Kragl

Wilhelm Keim

Guido Giffels

Peter Wasserscheid

Hartwig Hoecker

Nadine Derrien

Jan-Hendrik Schöbel

Steffen Koschmieder

Jonas Gossen

Giulia Rossetti

Bianca Altenburg

Nicolas Chatain

Marcus Frings

Marcel Felder

Joerg Brozio

Christian Dinter

Andreas Seger

The invention relates to compounds according to the general formula (1), and to the use thereof for production of a medicament, especially for treatment of a disorder associated with bromodomains, such as cancer.

Bromodomain inhibitors

The invention relates to chiral ionic liquids of the general formula[A][Y],whereby n=1 or 2, the anion [Y]is the anion of an organic or inorganic proton acid and the cation [A]an optically active organic ammonium cation with up to 50 carbon atoms, at least one chirality center and at least one functional group that can produce a coordination by forming hydrogen bridges or by providing free electron pairs. At least one chirality center is provided with a distance of up to 5 atomic bonds from the functional group. The invention also relates to a method for producing said chiral ionic liquids and to the use thereof in methods for the asymmetric synthesis, the asymmetric catalysis and for separating racemates.

Chiral ionic liquids

Polymeric homogeneous catalysts

It is known that dihydroquinine or dihydroquinidine derivatives can be successfully used as ligands in the enantioselective dihydroxylation. The new disclosed ligand systems based on dihydroquinine/quinidine, unlike the prior art ligands, can be recycled after enantioselective dihydroxylation by precipitating and filtering the reaction medium, and be reused in the reaction medium. Also disclosed are the ligand systems (I) and (IV), process for preparing the same and their use in the enantioselective dihydroxiation of double bonds.

Process for preparing MeO-Peg-protected dihydroquinine or dihydroquinidine derivatives, new dihydroquinine or dihydroquinidine derivatives and their use

Process for the formation of MeO-Peg-protected dihydroquinine or dihydro quinindine derivatives, new dihydroquinine-or dihyroquinidine derivatives as well as the use thereof. It is known that dihydroquinine or dihydroquinidine derivatives can be successfully used as ligands in the enantioselective dihydroxylation. The new disclosed ligand systems based on dihydroquinine/quinidine, unlike the prior art ligands, can be recycled after enantioselective dihydroxylation by precipitating and filtering the reaction medium, and be reused in the reaction medium. Also disclosed are the ligand systems (I) and (IV), process for preparing the same and their use in the enantioselective dihydroxiation of double bonds.

The invention involves a procedure for the catalytic enantioselective reduction of ketones to chiral alcohols. Heretofore, this reaction was carried out batch-wise. Because, in this procedure, one utilizes a catalyst increased in size with polymer, it is possible to carry out the reaction in a quasi-continuous manner in a membrane reactor. In contrast to the state of the art, one thus dramatically increases the operative life of the catalyst.

Process for the catalytic enantioselective reduction of ketones

Growing community of inventors

Aachen, Germany

Carsten Bolm